Overview
| MDL | MFCD23136998 |
|---|
| Molecular Weight | 280.66 |
|---|
| Molecular Formula | C12H9ClN2O4 |
|---|
| SMILES | O=C(O)CNC(C1=C(O)C2=C(C(Cl)=N1)C=CC=C2)=O |
|---|
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg |
| 1 mM | 3.5630 mL | 17.8152 mL | 35.6303 mL |
| 5 mM | 0.7126 mL | 3.5630 mL | 7.1261 mL |
| 10 mM | 0.3563 mL | 1.7815 mL | 3.5630 mL |
| 50 mM | 0.0713 mL | 0.3563 mL | 0.7126 mL |
Description
FG-2216 is a potent, and orally active inhibitor with of 3.9 μM for . Phase 2.
Targets
PHD2 [1]
(Cell-free assay) |
| 3.9 μM |
In vitro
FG-2216 shows the ability to stabilize HIF-α to stimulate EPO secretion.
In vivo
In male rhesus macaques, FG-2216 (60 mg/kg, p.o.), induces significant and reversible Epo induction, and induces a small elevation of HbF expression.
